Phytochemicals Nobiletin and Eriodictyol Can Help Suppress Neuroinflammation Caused by SARS-CoV-2 Spike Protein

Medical News: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has introduced unprecedented challenges to global healthcare. Beyond the well-documented respiratory effects, SARS-CoV-2 has been shown to have profound neurological impacts. These effects, particularly in the form of neuroinflammation, have become an area of critical concern for researchers.


Phytochemicals Nobiletin and Eriodictyol Can Help Suppress Neuroinflammation Caused by SARS-CoV-2 Spike Protein

Neuroinflammation, characterized by the activation of microglial cells in the brain, plays a significant role in the development of numerous neurological and neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease.
 
A recent study conducted by scientists from Tufts University School of Medicine in Boston, Massachusetts, and the Nova Southeastern University in Fort Lauderdale, Florida, explores the potential of two natural compounds, nobiletin and eriodictyol, in mitigating neuroinflammation triggered by the SARS-CoV-2 spike protein. This Medical News report highlights the findings and implications of this research, which provides new hope for managing the neurological consequences of COVID-19.
 
Nobiletin and Eriodictyol: Nature’s Anti-Inflammatory Agents
Nobiletin, a flavonoid extracted from citrus fruits, has long been studied for its potent anti-inflammatory, antioxidant, and neuroprotective properties. Similarly, eriodictyol, found in citrus and other plants, boasts anti-inflammatory and neuroprotective capabilities. Despite their promising properties, their specific impact on neuroinflammation induced by pathogens like SARS-CoV-2 has remained largely unexplored - until now.
 
The study investigated how these phytochemicals influence the inflammatory response in human microglial cells. These immune cells play a vital role in maintaining brain health but can exacerbate damage when overstimulated by pathogens or toxins, such as the SARS-CoV-2 spike protein.
 
Research Methodology and Key Findings
The researchers used an in vitro human microglial cell model to study the effects of nobiletin and eriodictyol. Cells were pre-treated with these flavonoids at various concentrations (10, 50, and 100 µM) for two hours before being exposed to the SARS-CoV-2 spike protein. Following a 24-hour incubation period, the release of key pro-inflammatory mediators, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), chemokine CXCL8, and matrix metalloproteinase-9 (MMP-9), was measured using enzyme-linked immunosorbent assays (ELISA).
 
The study revealed that both nobiletin and eriodictyol significantly inhibited the release of these inflammatory mediators. The suppression was most pronounced at a concentration of 100 µM. Notably:
 
-IL-1β and IL-6 Reduction: Both compounds effectively reduced the levels of these cytokines, which are closely linked to inflammation and neuron al damage.
 
-CXCL8 and MMP-9 Suppression: The flavonoids also curtailed the release of CXCL8 and MMP-9, both of which disrupt neuronal connectivity and compromise the blood-brain barrier.
 
-Interestingly, nobiletin demonstrated some inhibitory effects even at the lowest concentration of 10 µM, suggesting its potential efficacy at lower doses. This discovery emphasizes the compounds' therapeutic potential in reducing SARS-CoV-2-induced neuroinflammation.
 
The Role of the SARS-CoV-2 Spike Protein
The SARS-CoV-2 spike protein plays a pivotal role in the virus's ability to infect human cells. However, it has also been found to directly stimulate microglia, triggering the release of inflammatory mediators. Prolonged microglial activation not only damages neurons but also exacerbates conditions like “long COVID,” characterized by persistent cognitive issues, fatigue, and other neurological symptoms.
 
This research highlights how nobiletin and eriodictyol can counteract this harmful process by curbing the inflammatory response, potentially paving the way for new treatments for long COVID and other neuroinflammatory disorders.
 
Broader Implications for Neurodegenerative Diseases
The implications of this study extend beyond COVID-19. Microglial activation is a hallmark of many neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Elevated levels of inflammatory mediators like IL-1β, IL-6, and MMP-9 have been linked to these conditions. By suppressing these mediators, nobiletin and eriodictyol could offer therapeutic benefits across a range of neurological disorders.
 
The study’s findings also align with previous research demonstrating the neuroprotective effects of nobiletin in Alzheimer’s models, where it mitigates beta-amyloid toxicity and cognitive decline. Similarly, eriodictyol has shown promise in experimental stroke models, reducing neuroinflammation and improving cognitive outcomes.
 
Challenges and Future Directions
Despite the promising results, challenges remain. One significant hurdle is the poor water solubility of flavonoids, which can limit their bioavailability and effectiveness in therapeutic applications. However, eriodictyol's planar structure offers better solubility compared to other flavonoids, making it a more practical candidate for drug development.
 
Future research should focus on optimizing the delivery and formulation of these compounds to enhance their efficacy. Clinical trials are also needed to validate these findings in human populations and explore their potential in treating long COVID and other neuroinflammatory diseases.
 
Conclusion
This study underscores the potential of nobiletin and eriodictyol as natural inhibitors of neuroinflammation, particularly in the context of SARS-CoV-2 infection. By suppressing the release of key pro-inflammatory mediators from microglial cells, these compounds could play a vital role in managing the neurological complications associated with COVID-19 and beyond.
 
The therapeutic promise of these flavonoids extends to a broader spectrum of neurodegenerative diseases, offering hope for patients grappling with chronic inflammation and cognitive decline. However, further research and clinical trials are essential to translate these findings into practical treatments.
 
The study findings were published in the peer-reviewed International Journal of Molecular Sciences.
https://www.mdpi.com/1422-0067/26/2/636
 
For the latest on Neuroinflammation, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/study-finds-that-persistent-post-covid-headaches-are-due-to-neuroinflammation
 
https://www.thailandmedical.news/news/neuroinflammation-in-the-brainstem-and-its-link-to-pots-and-long-covid
 
https://www.thailandmedical.news/news/lactoferrin-and-its-promising-role-in-combating-neuroinflammation-and-promoting-neuronal-health
 
https://www.thailandmedical.news/news/neuroinflammation-and-new-strategies-for-brain-health
 
https://www.thailandmedical.news/news/the-phytochemical-honokiol-from-the-magnolia-tree-combats-neuroinflammation-and-brain-aging
 
https://www.thailandmedical.news/news/study-finds-that-mpox-virus-infects-human-astrocytes-causing-neuroinflammation-and-eventual-brain-damage
 
https://www.thailandmedical.news/news/covid-19-causes-the-upregulation-of-neuroinflammation-associated-genes-in-the-brain